Publications by authors named "P Chiarini"

Article Synopsis
  • A woman with heavily treated ROS1-positive non-small cell lung cancer (NSCLC) showed a clinically significant response to the drug repotrectinib for meningeal carcinomatosis, which is often seen in advanced NSCLC cases.
  • This is notable since there haven't been previous reports on repotrectinib's effectiveness for treating this condition despite its increased prevalence due to better life expectancy for patients.
  • The study found the drug at active levels in the cerebrospinal fluid, but the brief response underscores the need for new ROS1-tyrosine kinase inhibitors that can effectively cross the blood-brain barrier.
View Article and Find Full Text PDF

Introduction: Several functional neuroimaging studies on healthy controls and patients with migraine with aura have shown that the activation of functional networks during visual stimulation is not restricted to the striate system, but also includes several extrastriate networks.

Methods: Before and after 4 min of visual stimulation with a checkerboard pattern, we collected functional MRI in 21 migraine with aura (MwA) patients and 18 healthy subjects (HS). For each recording session, we identified independent resting-state networks in each group and correlated network connection strength changes with clinical disease features.

View Article and Find Full Text PDF

Brain iron load is one of the most important neuropathological hallmarks in movement disorders. Specifically, the iron provides most of the paramagnetic metal signals in the brain and its accumulation seems to play a key role, although not completely explained, in the degeneration of the basal ganglia, as well as other brain structures. Moreover, iron distribution patterns have been implicated in depicting different movement disorders.

View Article and Find Full Text PDF

Introduction: The efficacy of immune checkpoint inhibitors in patients with brain metastases (BMs) from non-oncogene addicted non-small cell lung cancer (NSCLC) is under investigation. Here, we sought to determine the optimal management of NSCLCs with PD-L1 ≥ 50% and asymptomatic BMs who were treated with first-line pembrolizumab.

Methods: Thirty patients from 15 institutions with PD-L1 ≥ 50% NSCLC had asymptomatic BMs, and met inclusion criteria.

View Article and Find Full Text PDF